Moe SM, et al. - Researchers investigated the association of genetic components with cardiovascular mortality in dialysis patients among participants from the EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events (EVOLVE) trial, a randomized trial conducted in patients receiving hemodialysis with secondary hyperparathyroidism, comparing cinacalcet to placebo on a background of usual care. They carried out a meta-analysis of European Ancestry (EA) and African Ancestry (AfAn) patients with end-stage kidney disease, wherein, they found that the C allele in rs5186 in AGTR1 was related to higher rates of death and major cardiovascular events. Associations of single-nucleotide polymorphisms in angiotensin-converting enzyme with sudden cardiac death were also observed.